1 Jager RD, Mieler WF & Miller JW (2008) Age-related macular degeneration. N Engl J Med 358, 2606–2617.
2 Muni RH, Altaweel M, Tennant M, et al. (2008) Agreement among Canadian retina specialists in the determination of treatment eligibility for photodynamic therapy in age-related macular degeneration. Retina 28, 1421–1426.
3 Klein R, Peto T, Bird A, et al. (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 137, 486–495.
4 Evans JR, Fletcher AE & Wormald RPL (2004) Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology 111, 513–517.
5 Friedman DS, O'Colmain BJ, Muñoz B, et al. (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122, 564–572.
6 Khan JC, Shahid H, Thurlby DA, et al. (2006) Age-related macular degeneration and sun exposure, iris colour, and skin sensitivity to sunlight. Br J Ophthalmol 90, 29–32.
7 Klein RJ, Zeiss C, Chew EY, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308, 385–389.
8 Schmidt S, Haines JL, Postel EA, et al. (2005) Joint effects of smoking history and APOE genotypes in age-related macular degeneration. Mol Vis 11, 941–949.
9 Subramanian ML, Ness S, Abedi G, et al. (2009) Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 148, 875–882.
10 Thornton J, Edwards R, Mitchell P, et al. (2005) Smoking and age-related macular degeneration: a review of association. Eye 19, 935–944.
11 Dillon J, Zhenga L, Merriama JC, et al. (2004) Transmission of light to the aging human retina: possible implications for age-related macular degeneration. Exp Eye Res 79, 753–759.
12 Smith W, Assink J, Klein R, et al. (2001) Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 108, 697–704.
13 Kowluru RA, Menon B & Gierhart D (2008) Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rat. Invest Ophthalmol Vis Sci 49, 1645–1651.
14 Cai J, Nelson K, Wu M, et al. (2000) Oxidative damage and protection of RPE. Prog Retin Eye Res 19, 205–221.
15 Izumi-Nagai K, Nagai N, Ohgami K, et al. (2007) Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arterioscler Thromb Vasc Biol 27, 2555–2562.
16 Margrain TH, Boulton M, Marshall J, et al. (2004) Do blue light filters confer protection against age-related macular degeneration? Prog Ret Eye Res 23, 523–531.
17 Krishnadev N, Meleth AD & Chew EY (2010) Nutritional supplements for age-related macular degeneration. Curr Opin Ophthalmol 21, 184–189.
18 Haegele AD, Gillette C, O'Neill C, et al. (2000) Plasma xanthophyll carotenoids correlate inversely with indices of oxidative DNA damage and lipid peroxidation. Cancer Epidemiol Biomark Prev 9, 421–425.
19 Thomson LR, Toyoda Y, Langner A, et al. (2002) Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. Invest Ophthalmol Vis Sci 43, 3538–3549.
20 Junghans A, Sies H & Stahl W (2001) Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch Biochem Biophys 391, 160–164.
21 Flood V, Smith W, Wang JJ, et al. (2002) Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 109, 2272–2278.
22 Cho E, Seddon JM, Rosner B, et al. (2004) Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 122, 883–892.
23 van Leeuwen R, Boekhoorn S, Vingerling JR, et al. (2005) Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 294, 3101–3107.
24 Tan JS, Wang JJ, Flood V, et al. (2008) Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 115, 334–341.
26 Higgins JP, Thompson SG, Deeks JJ, et al. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557–560.
27 Egger M, Davey Smith G, Schneider M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634.
28 Sterne JA & Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54, 1046–1055.
29 Van den Langenberg GM, Mares PJ, Klein R, et al. (1998) Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 148, 204–214.
30 Moeller S, Parekh N, Tinker L, et al. (2006) Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol 124, 1151–1162.
31 Cho E, Hankinson SE, Rosner B, et al. (2008) Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. Am J Clin Nutr 87, 1837–1843.
32 Khachik F, Bernstein PS & Garland DL (1997) Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 38, 1802–1811.
33 Ma L & Lin XM (2010) Effects of lutein and zeaxanthin on aspects of eye health. J Sci Food Agric 90, 2–12.
34 Rapp LM, Maple SS & Choi JH (2000) Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Invest Ophthalmol Vis Sci 41, 1200–1209.
35 Stahl W & Sies H (1993) Physical quenching of singlet oxygen and cis–trans isomerization of carotenoids. Ann NY Acad Sci 691, 10–19.
36 Krinsky NI, Landrum JT & Bone RA (2003) Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr 23, 171–201.
37 Thomson LR, Toyoda Y, Delori FC, et al. (2002) Long term dietary supplementation with zeaxanthin reduces photoreceptor death in light-damaged Japanese quail. Exp Eye Res 75, 529–542.
38 Donoso LA, Kim D, Frost A, et al. (2006) The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 51, 137–152.
39 Seddon JM, Gensler G, Milton RC, et al. (2004) Association between C-reactive protein and age-related macular degeneration. JAMA 291, 704–710.
40 Kowluru RA, Menon B & Gierhart D (2008) Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rat. Invest Ophthalmol Vis Sci 49, 1645–1651.
41 Seddon J, Anani A, Sperduto R, et al. (1994) Dietary carotenoids, vitamin A, C, E and advanced age-related macular degeneration. Eye Disease Case Controlled Study Group. JAMA 272, 1413–1420.
42 AREDS Research Group (2007) The relationship of dietary carotenoid and vitamin A, E and C intake with age-related macular degeneration in a case–control study. AREDS report no. 22. Arch Ophthalmol 125, 1225–1232.
43 Mares-Perlman JA, Fisher AI, Klein R, et al. (2001) Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 153, 424–432.
44 Chiu CJ, Milton RC, Klein R, et al. (2009) Dietary compound score and risk of age-related macular degeneration in the Age-related Eye Disease Study. Ophthalmology 116, 939–946.
45 Bone RA, Landrum JT, Dixon Z, et al. (2000) Lutein and zeaxanthin in the eyes, serum and diet of human subjects. Exp Eye Res 71, 239–245.
46 Zhang X, Shu XO, Chow WH, et al. (2008) Body mass index at various ages and mortality in Chinese women: impact of potential methodological biases. Int J Obes 32, 1130–1136.
47 Berendschot TT, Willemse-Assink JJ, Bastiaanse M, et al. (2002) Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci 43, 1928–1932.
48 Jahn C, Wustemeyer H, Brinkmann C, et al. (2005) Macular pigment density in age-related maculopathy. Graefes Arch Clin Exp Ophthalmol 243, 222–227.
49 Beatty S, Murray IJ, Henson DB, et al. (2001) Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 42, 439–446.
50 Wüstemeyer H, Jahn C, Nestler A, et al. (2002) A new instrument for the quantification of macular pigment density: first results in patients with AMD and healthy subjects. Graefes Arch Clin Exp Ophthalmol 240, 666–671.
51 Bone R, Landrum J, Mayne S, et al. (2001) Macular pigment in donor eyes with and without AMD: a case–controlled study. Invest Ophthalmol Vis Sci 42, 235–240.
52 Choi JS, Kim D, Hong Y, et al. (2006) Inhibition of nNOS and COX-2 expression by lutein in acute retinal ischemia. Nutrition 22, 668–671.
53 Freeman WR, El-Bradey M & Plummer DJ (2004) Scanning laser entoptic perimetry for the detection of age-related macular degeneration. Arch Ophthalmol 122, 1647–1651.
54 Van den Langenberg GM, Brady WE, Nebeling LC, et al. (1996) Influence of using different sources of carotenoid data in epidemiologic studies. J Am Diet Assoc 96, 1271–1275.
55 Seddon J, George S & Rosner B (2006) Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration. The US twin study of age-related macular degeneration. Arch Ophthalmol 124, 995–1001.
56 Seddon JM, Cote J, Page WF, et al. (2005) The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 123, 321–327.